Amneal Takes A Step Forward On Biosimilars
FDA Accepts Filing For Bevacizumab Rival To Avastin, Partnered With Mabxience
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.
You may also be interested in...
Amneal continues to focus on new generics launches as the company sees its quarterly and half-yearly revenues increase on the back of its new launches and generics portfolio. The US-based company said that it was looking to continue its shift towards complex generics, as it considers eventually building in-house capabilities for biosimilars.
Amneal has broadened its complex generics portfolio by gaining FDA approval for its generic version of ophthalmic combination medicine TobraDex.
Keeping Track: StrataGraft Continues US FDA’s Biologic Center Approvals Streak; Another CRL For Avenue’s Tramadol IV
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.